Laboratory of Immunobiochemistry Site Visit

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Center for Biologics Evaluation and Research
Allergenic Products Advisory Committee, March 15, 2002 n Lab overview n Research update Site visit summarySite visit summary Rabins projectsRabins projects.
Laboratory of Respiratory and Special Pathogens. History of the Laboratories Laboratory of Pertussis Laboratory of Respiratory and Special Pathogens Laboratory.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
1/22 Efficacy Review of Allergen Extracts (2003 – Present) Jay E. Slater, MD Director, DBPAP.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 25 October 2013.
Overview of the Division of Viral Products
Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
U of Arizona Innovation Conference 20 September 2011 Marlene E. Haffner, MD, MPH Haffner Associates, LLC.
Laboratory of Immunobiochemistry and ISO Accreditation Sandra Menzies, M.S., Consumer Safety Officer Laboratory of Immunobiochemistry, CBER, FDA.
August 12, Meaningful Use *** UDOH Informatics Brown Bag Robert T Rolfs, MD, MPH.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Michael J. Brennan, Ph.D. for Kathryn M. Carbone, M.D. Associate Director for.
Denise K. Gavin, Ph.D. Division of Cellular and Gene Therapies
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 28 February 2012.
1 Change of Potency Assay for Standardized Short Ragweed Pollen and Cat Allergen Extracts Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry CBER/OVRR/DBPAP.
Allergen regulation in the future : what will be the place for recombinant allergens ? Jacqueline DAYAN-KENIGSBERG European Academy of Allergology and.
Ensuring Product Quality in Gene Transfer Clinical Trials
FDA Regulation of Bacterial Vaccines
DHHS/NIH/NIAID/DAIDS September 8, 2004 ADDRESSING THE INFORMATIONAL REQUIREMENTS OF REGULATORY AGENCIES IN INTERNATIONAL VACCINE DEVELOPMENT STUART Z.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
1 Report on the safety of non-standardized allergenic extracts Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry Division of Bacterial, Parasitic.
Laboratory of Immunobiochemistry site visit Jay E. Slater, MD FDA/CBER/OVRR/DBPAP June 29, 2006.
1 Environmental Exposure Units for Phase 3 Studies Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry Center for Biologics Evaluation and Research.
U.S. Food and Drug Administration
T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.
Efficacy Review of Allergenic Extracts: Background (1972 – 1985) Jay E. Slater, MD Director, DBPAP.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.
1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.
LIB site visit January 24, 2002 Jay E. Slater, MD Laboratory of Immunobiochemistry FDA/CBER/OVRR/DBPAP.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.
1/22 Potential Next Steps Jay E. Slater, MD Director, DBPAP.
Laboratory of Immunobiochemistry Allergenic Products Advisory Committee, April 8, 2003.
Allergenic Extracts – Precipitates Jennifer Bridgewater, M.P.H. CBER, DBPAP.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 12 May 2011.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
Recombinant allergens: what needs to come next?. Where we are with natural allergens n All natural, mixes based largely on an unselective extraction of.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 18 March 2009.
Thomas S. Bundt, PhD., FACHE COL, MS Commander, USAMRIID
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Office of Vaccines Research and Review
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Overview Laboratory of Bacterial Polysaccharides From cover - Science, 23 March, 2001.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.
German cockroach allergen standardization – progress report.
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.
USP: Water for Pharmaceutical Purposes NCSLI – Metrological Traceability in Pure Water Testing August 22, 2011 Antonio Hernandez-Cardoso Senior Scientific.
BIOTECHNOLOGY A Review. What is biotechnology? Any technological application that uses biological systems, living organisms or derivatives thereof, to.
Overview of vaccines prequalification
The Lifecycle of Pharmaceutical products
Innate microbial sensors and their relevance to allergy
Pharmacy practice experience I
The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts  Jay E. Slater, MD, Sandra L. Menzies,
Presentation transcript:

Laboratory of Immunobiochemistry Site Visit Ronald L. Rabin, MD FDA/CBER/OVRR/DBPAP November 4, 2010

Laboratory of Immunobiochemistry (LIB) LIB supports the regulatory mission of CBER and FDA in assuring the safety and efficacy of allergenic products in the US original research directed research projects expert advice lot release data BLA and IND review

History of LIB Laboratory of Allergenic Products, Division of Bacterial Products Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology Allergenic Products Testing Lab Allergenic Products Research Lab Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products

Natural allergen extracts Complex mixtures of allergenic proteins, based largely on an unselective aqueous extraction of natural source material (pollens, insects, animals, foods, venoms) Used for Diagnosis (allergy skin testing) and Allergen immunotherapy Documented efficacy in the immunotherapy of allergic disease due to hymenoptera, ragweed, grass, cat, and dust mite allergen exposure

Natural allergen extracts Non-standardized products (n > 1000) Unitage uninformative (PNU/mL or w/v) Standardized products (n = 19) unitage correlates to biological potency mass units, BAU/mL, specific allergen controlled for potency and stability based on identity to US standard constitute a small minority of product number, but a greater percentage of product volume

How can we improve the use of natural allergen extracts? Increase the number of standardized products Improve the standardization of some current products by improving the definition of the measured allergens Increase purity standards selective extraction techniques, purification Improve characterization methods

Recombinant / engineered allergens Current: Potent research tools dissect immune responses modify immune responses study allergen structure determine structure-function relationships generate novel products

Recombinant/engineered allergens Opportunities (positive): Allergenicity  immunogenicity Possible standardization tools Greater purity and consistency of product Greater product stability (both due to purity and engineering) Improve delivery systems (in ways not possible using native proteins) Opportunities (negative): Challenges to standardization allergenicity  immunogenicity  potency unique products with different biological features Indications will be very specific IT products may be ineffective for diagnosis Diagnostic products may be ineffective for IT Usage may be population-specific

The last dedicated site visit for LIB was in June 2006 relevant to the mission of the laboratory and deserved continued support from the agency

Staffing Ronald L. Rabin, MD – Lab Chief Philippa Hillyer, Ph.D. Ashraf El Fiky MD, Ph.D.-Visiting Associate Zeng Zhao, MD, Visiting Associate Jay Slater, MD – Supervisory Medical Officer Taruna Khurana, Ph.D. Regulatory Staff Sandra Menzies, MS–Consumer Safety Officer Cherry Valerio Katia Dobrovolskaia Aaron Chen MS Mona Febus

LIB regulatory activities (see Briefing Document, pp.12 - 13) Lot release US reference standards distribution maintenance Regulatory review IND applications BLA applications and supplements Implementation of category IIIA product reclassification to re-evaluate over 1200 non-standardized prodcuts for efficacy ISO (International Standards Organization) 17025 compliance for accreditation to ensure stringent documentation and protocols for SOP Replace RID for Fel d1 and Amb a1 (cat and ragweed) with ELISA 13th Int’l Paul-Ehrlich-Seminar: Regulatory Control and Standardization of Allergenic Extracts. Washington, D.C. September, 2011 Lot release: we are the product related lab that tests for lot release IIIA: re-evaluate over 1200 products for efficacy ISO17025: stringent documentation and SOP protocols

Endotoxins in allergen extracts Scientific goals Allergen structure and function Biological activity and expression patterns of subtypes of types I and III IFN Multiplex allergen extract potency assay characterization of complex allergen extracts Endotoxins in allergen extracts Extract characterization Modifying allergic responses

Regulatory responsibility Regulatory correlates of LIB’s research program (see Briefing Document, p.15) Regulatory responsibility Research correlate Improved lot release capabilities for current and future products Allergen standardization Immunomodulatory approach to inner city asthma Multiplex allergen extract potency; cockroach allergen standardization Allergenic extract safety and efficacy Endotoxin Parameters of effective immunomodulation Types I and III IFN Novel approaches to immunotherapy